aspirin
/ Generic mfg.
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
21983
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
August 20, 2025
Navigating Obstetric Anesthesia in Aortic Stenosis: A Case of Tailored Epidural and ICU Delivery
(ASA 2025)
- "Low-dose aspirin was initiated week 20. Delivery occurred in the CICU with early, slow-titrated fentanyl/ropivacaine epidural and assisted second stage to avoid Valsalva. Patient remained stable and was discharged after 24 hours of monitoring with her newborn at bedside."
Clinical • Anesthesia • Cardiovascular • Obstetrics
August 20, 2025
Bleeding Risks and Urgent Orthopedic Surgery: Navigating Infection, Anticoagulation, and Hemodynamic Instability in a Congenital Cardiac Patient
(ASA 2025)
- "Despite recent aspirin and rivaroxaban use, orthopedic surgery felt urgent necessity for hardware removal. Given Andexanet alfa unavailability, hematology and cardiac surgery prioritized bleeding risk and planned reversal with 4FPCC at 25 units/kg prior to incision.In the OR, purulent fluid was found around the hardware. She developed hypotension with blood loss. She was given transfusions and underwent successful wound-washout, transferred to PICU, and discharged post-op day 5 with aspirin."
Clinical • Surgery • Cardiovascular • Hematological Disorders • Hypotension • Infectious Disease • Orthopedics
August 20, 2025
Anesthetic Considerations for a Pregnant Patient with Immune Thrombocytopenia on Aspirin Therapy Undergoing Cesarean Delivery: A Case Report
(ASA 2025)
- "The patient stabilized postoperatively with favorable maternal and fetal outcomes. This case underscores the need to refine guidelines on anesthetic management of pregnant patients with ITP on aspirin therapy to improve individualized delivery planning."
Case report • Clinical • Anesthesia • Cardiovascular • Diabetes • Gestational Diabetes • Gynecology • Hematological Disorders • Hypertension • Immune Thrombocytopenic Purpura • Metabolic Disorders • Postpartum Hemorrhage • Thrombocytopenia • Thrombocytopenic Purpura
August 20, 2025
The Cuff Did It: A Benign Rash Mimic in a Diabetic Vascular Patient
(ASA 2025)
- "She was maintained on aspirin, with apixaban and clopidogrel appropriately held preoperatively. The cuff and IV were removed, the patient remained hemodynamically stable, and surgery proceeded without complication. This case highlights the importance of recognizing this rare but harmless dermatologic finding to avoid unnecessary alarm or intervention during anesthetic care."
Clinical • Anesthesia • Cardiovascular • Diabetes • Metabolic Disorders • Peripheral Arterial Disease • Type 1 Diabetes Mellitus
September 10, 2025
Effect of Aspirin on Grip Strength and Gait Speed in Community-Dwelling Older Adults in the ASPirin in Reducing Events in the Elderly (ASPREE) Study.
(PubMed, J Gerontol A Biol Sci Med Sci)
- "Low-dose aspirin use in relatively healthy older people did not affect gait speed or grip strength over time or reduce the risk of weakness and slowness."
Journal • Alzheimer's Disease • Cardiovascular • CNS Disorders • Cognitive Disorders • Dementia
September 10, 2025
Carotid artery stenting in JAK2 V617F-positive essential thrombocythemia with symptomatic internal carotid artery stenosis: a case report.
(PubMed, Front Cardiovasc Med)
- "Aggressive perioperative platelet and inflammation control, employing hydroxyurea, aspirin, and ticagrelor, was instrumental in mitigating the heightened thrombosis risk associated with the JAK2 V617F mutation. This case underscores that ET patients with the JAK2 V617F mutation face a substantial risk of thrombotic recurrence. It highlights the critical importance of rigorous preoperative platelet control, personalized antiplatelet therapy guided by pharmacogenomic principles, and multidisciplinary management in high-risk ET patients undergoing CAS."
Journal • Cardiovascular • CNS Disorders • Essential Thrombocythemia • Hematological Disorders • Myeloproliferative Neoplasm • Oncology • Thrombocytosis • Thrombosis • JAK2
September 10, 2025
Sputum Eosinophil and Macrophage Changes After Aspirin Challenge in Patients With Nonsteroidal Anti-Inflammatory Drug-Exacerbated Respiratory Disease.
(PubMed, Clin Transl Allergy)
- "In N-ERD, sputum eosinophil percentage decreased after aspirin challenge regardless of administration route. In both N-ERD and ATA, sputum macrophage percentage decreased after oral aspirin challenge."
Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases
September 10, 2025
Antiplatelet therapy and central nervous system hematomas: a cohort study using real-world data from the FAERS and vigiaccess databases.
(PubMed, Int J Surg)
- "We found a disproportionately significant association between antiplatelet therapy and CNS-related hematomas, with distinct patterns observed across drug types, patient demographics, and temporal profiles. These findings provide critical insights to inform risk stratification, clinical decision-making, and safety monitoring in patients undergoing antiplatelet therapy."
Journal • Real-world evidence • Atherosclerosis • Cardiovascular • CNS Disorders
September 10, 2025
Clinical Characteristics and Disease Burden of Wheat Allergy Dependent on Augmentation Factors in Recreationally Active and Trained Individuals.
(PubMed, Scand J Med Sci Sports)
- "In the diagnostic challenge tests, 90% reacted to wheat gluten alone in high doses or in combination with acetylsalicylic acid...Weight training may be less likely to trigger reactions than endurance activities. Timely diagnosis through challenge tests and comprehensive education and management effectively restore exercise participation and QOL."
Journal • Allergy • Dermatology • Immunology • Urticaria
July 01, 2025
A DOUBLE-EDGED PILL: ASPIRIN-INDUCED KOUNIS SYNDROME [WITHDRAWN]
(CHEST 2025)
- No abstract available
Cardiovascular
September 10, 2025
Addition of Dupilumab for Patients with Aspirin-Exacerbated Respiratory Disease who have Poor Response to Aspirin Therapy After Desensitization.
(PubMed, J Allergy Clin Immunol Pract)
- No abstract available
Journal • Chronic Rhinosinusitis With Nasal Polyps • Immunology • Nasal Polyps • Otorhinolaryngology • Respiratory Diseases • Sinusitis
September 09, 2025
Postoperative Stroke Through a Patent Foramen Ovale in a Patient With Lung Cancer: A Case Report.
(PubMed, Cureus)
- "Treatment was initiated with aspirin on postoperative day 2, switched to apixaban after PFO confirmation. Perioperative strokes are often observed in patients with multiple underlying risk factors. In pulmonary resection, pulmonary vein stump thrombosis has been proposed as a causative mechanism, although PBE through PFO warrants consideration as an important alternative etiology because lung resection creates ideal conditions for PBE by combining increased venous thrombosis risk with elevated right heart pressures due to loss of the pulmonary vascular bed."
Journal • Atrial Fibrillation • Cardiovascular • CNS Disorders • Diabetes • Hematological Disorders • Hypertension • Lung Cancer • Metabolic Disorders • Oncology • Solid Tumor • Thrombosis
September 09, 2025
Genetically predicted causal relationship between aspirin and colorectal cancer in individuals of European ancestry.
(PubMed, Medicine (Baltimore))
- "Sensitivity results suggested the robustness of our findings. Our study reveals a causal relationship between aspirin and CRC, which provides a new basis for future clinical practice and CRC prevention and treatment research."
Causal relationship • Journal • Colorectal Cancer • Oncology • Solid Tumor
September 09, 2025
Estimating the long-term effects of aspirin for primary prevention.
(PubMed, Eur Heart J)
- No abstract available
Journal
September 09, 2025
Delayed Diagnosis Salicylate Toxicity With Confirmed Cerebrospinal Fluid Salicylate Concentration: A Case Report of Altered Mental Status Without Neuroglycopenia and With Coagulopathy.
(PubMed, Cureus)
- "Although we do not recommend routine CSF testing in salicylate toxicity cases, analysis of CSF could shed insight into salicylate-induced encephalopathy. This case illustrates that prompt recognition and treatment of toxicity is key, as delayed diagnosis can increase morbidity and mortality."
Journal • CNS Disorders • Hematological Disorders • Infectious Disease • Pain
September 09, 2025
Mendelian randomization study: The association between pain, analgesics, and frailty.
(PubMed, Medicine (Baltimore))
- "This bidirectional two-sample Mendelian randomization study included summary statistics of pain at different sites (headache, neck or shoulder pain, stomach or abdominal pain, hip pain, back pain, and knee pain), analgesics (aspirin, ibuprofen, paracetamol, and morphine), and frailty index. Findings suggest that common analgesic use (aspirin, ibuprofen, and paracetamol) may contribute to frailty risk, while frailty increases analgesic use. Results do not support using analgesic-based pain management for frailty improvement."
Journal • Back Pain • Musculoskeletal Pain • Pain
August 30, 2025
A Case of Extramedullary Plasmacytoma Involving the Pancreas
(ACG 2025)
- "The patient began systemic treatment with daratumumab, lenalidomide, aspirin, acyclovir, and dexamethasone. Extramedullary plasmacytoma (EMP) of the pancreas is rare and often appears similar to pancreatic adenocarcinoma, typically causing jaundice and abdominal pain. Early and accurate diagnosis can lead to more effective treatment, reducing unnecessary surgeries and significantly improving outcomes.Figure: Pancreatic biopsy shows predominant population of atypical plasma cells that are CD138 positive: Hematoxylin and Eosin staining, magnification x 40 and x100. Figure: Immunostain CD138 Highlighting Plasma Cells, magnification x40"
Clinical • Anemia • Cardiovascular • Dyslipidemia • Endocrine Disorders • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Hepatology • Hypertension • Melanoma • Multiple Myeloma • Pancreatic Adenocarcinoma • Pancreatic Cancer • Plasmacytoma • Solid Tumor • CD38 • SDC1
August 30, 2025
Primary Budd-Chiari Syndrome: A Silent Threat
(ACG 2025)
- "Due to her liver anatomy, she is not a candidate for TIPS procedure, and she was scheduled for outpatient routine paracentesis and listed for liver transplant and discharged with spironolactone, furosemide, enoxaparin, aspirin, and hydroxyurea. PBCS is extremely rare, ~ 1 case per million per year, more common in women 30-40s. (C) Showing multiple collaterals from chronic hepatic vein occlusion. (D) Yellow arrow showing intrahepatic IVC narrowing and red arrow showing engorgement corresponding to the CT images."
Cardiovascular • Essential Thrombocythemia • Fibrosis • Hepatology • Immunology • Infectious Disease • Myeloproliferative Neoplasm • Portal Hypertension • Rare Diseases • Thrombocytosis • Thrombosis
July 22, 2025
ATTEND: Randomized Phase III Trial of Tislelizumab and Chemotherapy With or Without Diphenhydramine in Advanced Non-Small Cell Lung Cancer
(IASLC-WCLC 2025)
- "Research has demonstrated that the concurrent use of non-steroidal anti-inflammatory drugs can significantly enhance the objective response rate in patients treated with nivolumab. Additionally, the co-administration of aspirin has been shown to lower the mortality rate among patients receiving immunotherapy. Furthermore, the H1 receptor antagonist loratadine has been found to improve survival outcomes for NSCLC...Patients are randomized (1:1) to receive either tislelizumab (200 mg) plus platinum-based doublet chemotherapy (pemetrexed 500 mg/m2 for non-squamous cell carcinoma or albumin-bound paclitaxel 260 mg/m2 for squamous cell carcinoma) every 3 weeks, with or without diphenhydramine (20 mg qd IM on day 0-2)...Secondary endpoints include objective response rate, overall survival, and toxicity profile. The ATTEND trial commenced in December 2024, and enrollment is ongoing across 19 centers in China."
Clinical • Metastases • P3 data • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma
September 09, 2025
Bulk and surface engineered drug delivery system of repurposed drug enhances low-dose gemcitabine efficacy in pancreatic cancer.
(PubMed, Int J Pharm)
- "Aspirin (ASP), a repurposed NSAID, has been shown to sensitize PDAC cells to GEM through modulation of multiple oncogenic and inflammatory pathways. The study exemplifies how the control of polymorphic form, release kinetics, and surface engineering can overcome key limitations of combination chemotherapy. These findings highlight a novel NSAID based delivery platform with potential to improve outcomes in pancreatic cancer therapy through a rational, mechanism-driven sustained release approach."
Journal • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor
August 30, 2025
A Rare Case of Giant Cell Arteritis Presenting With Progressive Dysphagia and Lingual Infarction
(ACG 2025)
- "Temporal artery biopsy revealed bilateral transmural inflammation, consistent with GCA, though giant cells were not seen.Treatment included prednisone 60 mg daily and aspirin 81 mg daily. First-line therapy includes high-dose steroids and aspirin, but refractory cases may require advanced treatments like tocilizumab.GCA should be considered in elderly patients presenting with dysphagia and systemic symptoms, even in the absence of classic features. Prompt recognition and treatment are essential, making rare presentations valuable in improving patient care."
Clinical • Cardiovascular • Gastrointestinal Disorder • Giant Cell Arteritis • Immunology • Inflammation • Otorhinolaryngology • Vasculitis
July 31, 2025
BTK inhibitors potently impair platelet aggregation as a class effect independent of BTK specificity or dose in CLL and MCL.
(PubMed, J Clin Exp Hematop)
- "We investigated whether BTKi impaired platelet aggregation and adhesion in a drug- or dose-dependent manner in patients with CLL and MCL who received ibrutinib, acalabrutinib, or pirtobrutinib. Although the sample size was small, our results suggest the potential of impaired platelet adhesion as a candidate biomarker for estimating bleeding risk in patients receiving BTKi. Second, in BTKi-treated patients requiring anti-platelet agents, BTKi dose reduction may be considered, irrespective of BTK selectivity of the drug or whether aspirin or a P2Y12 receptor inhibitor is used."
Journal • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Mantle Cell Lymphoma • Oncology
August 16, 2025
Clinical and biological determinants of multimodal metronomic chemotherapy efficacy in chemo-refractory gastrointestinal cancers.
(PubMed, Int J Cancer)
- P=N/A | "Multimodal MC was administered continuously, combining low doses of capecitabine, cyclophosphamide, and aspirin. The presence of liver metastases, baseline plasmatic levels of Ang2 and CXCL14, as well as the induction of PD1 on T-cells are potential biomarkers for efficacy. These results feature a potential subset of diseases where MC might be a promising cost-effective and well-tolerated therapeutic option."
IO biomarker • Journal • Gastrointestinal Cancer • Oncology • Solid Tumor • ANGPT2 • CD4 • CD8 • CXCL14 • PD-1
August 28, 2025
NCI-2019-01192: Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery
(clinicaltrials.gov)
- P2 | N=12 | Active, not recruiting | Sponsor: Roswell Park Cancer Institute | Recruiting ➔ Active, not recruiting | N=30 ➔ 12 | Trial primary completion date: Nov 2026 ➔ Jun 2025
Biomarker • Enrollment change • Enrollment closed • Trial primary completion date • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor
August 12, 2025
Pharmacokinetics of dexamethasone in tuberculosis meningitis.
(PubMed, medRxiv)
- "This pharmacokinetic study was nested in a randomised controlled trial comparing the safety of high-dose rifampicin (oral, 35 mg/kg; intravenous, 20 mg/kg) plus linezolid, with or without aspirin, vs standard-dose rifampicin (10 mg/kg) for adults with HIV-associated TBM...Eight (18%) participants were on efavirenz-based ART and five (11%) were on a lopinavir/ritonavir-based regimen...This pharmacokinetic analysis of dexamethasone in adults with HIV-associated tuberculosis meningitis found high oral clearance (131 L/h), likely due to a drug-drug interaction with rifampicin. High-dose rifampicin had no additional effect on dexamethasone exposure compared with standard dose."
Journal • PK/PD data • CNS Disorders • Human Immunodeficiency Virus • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis
1 to 25
Of
21983
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880